NASDAQ · GHRS
GH Research PLC
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for GHRS: Nov 5, 2026
GH Research PLC Ordinary Shares is estimated to report earnings on 11/05/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 3 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.27. The reported EPS for the same quarter last year was $-0.23.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.27 | $-0.14 | $-0.38 | 3 |
| Dec 2026 | $-0.40 | $-0.31 | $-0.49 | 3 |
| Mar 2027 | $-0.35 | $-0.35 | $-0.35 | 1 |
| Jun 2027 | $-0.38 | $-0.38 | $-0.38 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
The Motley Fool · Zacks · RTTNews · Fintel- The Motley Fool · Jul 23, 9:05 AM EDTEli Lilly Is Acquiring a Psychedelic Medicine Biotech. Here's What You Need to Know.Eli Lilly is going to buy a psychedelic drug biotech called AtaiBeckley.
- Zacks · Jul 2, 11:28 AM EDTIs AtaiBeckley Stock Worth Buying After Its Stronger Rally in 2026?ATAI's 2026 rally has raised expectations as key pipeline milestones approach, leaving the stock's outlook increasingly tied to clinical execution and upcoming data.
- Zacks · Jul 2, 11:09 AM EDTAtaiBeckley Reflects a New Push for Rapid-Acting Mental Health DrugsATAI is pursuing rapid-acting mental health treatments with key late-stage catalysts ahead, but its outlook still hinges on clinical execution and pipeline progress.
- Zacks · Jul 2, 10:50 AM EDTAtaiBeckley Stock Outlook Depends on Key Pipeline Catalysts in 2026ATAI enters a catalyst-heavy 2026 as BPL-003 advances toward phase III, with upcoming pipeline milestones set to shape the clinical-stage biotech's outlook.
- RTTNews · Jun 5, 6:26 AM EDTGH Reports Primary Endpoint Met In Phase 2a For GH001 In Treating Post-Partum Depression(RTTNews) – GH Research PLC (GHRS), a clinical-stage biopharmaceutical company, on Thursday announced Phase 2a results for GH001 in treating post-partum depression (PPD). Results were published in The Journal of Clinical Psychiatry.
- RTTNews · Apr 20, 11:50 AM EDTGH Research Welcomes White House Order On Mental Health Treatments; Stock Up(RTTNews) – GH Research PLC (GHRS) has expressed strong support for the recent White House Executive Order aimed at accelerating medical treatments for serious mental illness.
- Fintel · Mar 27, 10:01 PM EDTGH Research (GHRS) Price Target Increased by 18.94% to 40.04The average one-year price target for GH Research (NasdaqGM:GHRS) has been revised to $40.04 / share. This is an increase of 18.94% from the prior estimate of $33.66 dated February 21, 2026. The price target is an average of many targets provided by analysts.
- Barchart · Jan 6, 1:30 PM ESTStocks Finish Higher on Strength in Chip Makers and Energy ProducersThe S&P 500 Index ($SPX ) (SPY ) on Monday closed up +0.64%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +1.23%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.77%. March E-mini S&P futures (ESH26 ) rose +0.64%, and March E-mini Nasdaq futures…
- Barchart · Jan 5, 5:48 PM ESTStocks Climb on AI Spending Optimism and Strength in Energy ProducersThe S&P 500 Index ($SPX ) (SPY ) today is up +0.54%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.99%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.78%. March E-mini S&P futures (ESH26 ) are up +0.58%, and March E-mini Nasdaq futures…
- Barchart · Jan 5, 5:38 PM ESTChip Makers and Energy Producers Lead Stock Indexes HigherThe S&P 500 Index ($SPX ) (SPY ) today is up +0.72%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +1.32%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.04%. March E-mini S&P futures (ESH26 ) are up +0.72%, and March E-mini Nasdaq futures…
- RTTNews · Jan 5, 9:01 AM ESTWhy GH Research Is Rising In Pre-market?(RTTNews) – GH Research PLC (GHRS) announced the FDA has lifted the clinical hold on its Investigational New Drug Application for GH001. GH Research said the clearance enables U.S. subject enrollment and progresses the company toward alignment of its development across major juri
- RTTNews · Jan 5, 6:24 AM ESTGH Research To Announce IND Status For GH001 And Phase 3 Trial In Treatment-resistant Depression(RTTNews) – GH Research PLC (GHRS), a clinical-stage biopharmaceutical company that develops treatment for depression, announced that it will provide an update on the status of its Investigational New Drug Application or IND for its lead candidate GH001 with the U.S. Food and Dru
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for GH Research PLC from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.